Rule 901:14-2-13 | Laboratory testing.
(A) All hemp-derived cannabinoid products prior to being offered for sale shall be tested in accordance with this rule.
(B) Unless otherwise stated in paragraph (G) of this rule, the hemp processor shall select a random sample from every batch or lot of hemp-derived cannabinoid products produced at their facility that is of sufficient quantity to perform the required tests. The sample shall be tested by a testing laboratory which meets the requirements of rule 901:14-2-14 of the Administrative Code.
(C) Unless otherwise stated in paragraph (G) of this rule, a processor shall have the testing laboratory test every required hemp-derived cannabinoid product sample for:
(1) Microbiological and fungal contaminates as listed in paragraph (A)(2)(a) of rule 901:14-2-19 of the Administrative Code;
(2) Cannabinoid potency including, at minimum:
(a) Delta-9-tetrahydrocannabinolic acid;
(b) Delta-9-tetrahydrocannabinol;
(c) Delta-8-tetrahydrocannabinol;
(d) Total tetrahydrocannabinol;
(e) Cannabidiolic acid;
(f) Cannabidiol; and
(g) All other cannabinoids listed on the product label.
(3) Mycotoxins as listed in paragraph (A)(2)(b) of rule 901:14-2-19 of the Administrative Code;
(4) Heavy metals as listed in (A)(2)(c) of rule 901:14-2-19 of the Administrative Code; and
(5) Residual solvents, if a solvent other than carbon dioxide was used in the extraction process, if applicable.
(D) The processor shall have the testing laboratory estimate and report the measurement of uncertainty with the test results for the cannabinoids listed in paragraph (C)(2) of this rule.
(E) The processor shall obtain from the testing laboratory a certificate of analysis that meets the requirements of rule 901:14-2-15 of the Administrative Code of every hemp-derived cannabinoid product sample tested.
(F) A processor shall not sell or otherwise distribute the hemp-derived cannabinoid product unless the product meets the standards set forth in Chapter 928. of the Revised Code and this chapter.
(G) Exceptions:
(1) Hemp-derived cannabinoid products that contain an intermediate hemp-derived cannabinoid product are exempt from the testing requirements found in paragraphs (C)(1) and (C)(3) to (C)(5) of this rule so long as:
(a) The intermediate hemp-derived cannabinoid products used in the product were acquired from a source identified in rule 901:14-2-10 of the Administrative Code; and
(b) The intermediate hemp-derived cannabinoid products were accompanied with a certificate of analysis that meets the requirements of rule 901:14-2-15 of the Administrative Code; and
(i) The certificate of analysis matches the batch or lot used in the production of the hemp-derived cannabinoid products by the processor; and
(ii) The certificate of analysis was generated by a laboratory which meets the requirements of rule 901:14-2-14 of the Administrative Code.
(2) Hemp-derived cannabinoid products that are cosmetics, perishable, or produced at retail for immediate ingestion, that contain an intermediate hemp-derived cannabinoid product, are exempt from the testing requirements found in paragraphs (C)(1) and (C)(3) to (C)(5) of this rule so long as:
(a) A written product formulation that is utilized for each batch of product is developed, kept on file, and made available to the department upon request;
(b) The intermediate hemp-derived cannabinoid products used in the product were acquired from a source identified in rule 901:14-2-10 of the Administrative Code;
(c) The intermediate hemp-derived cannabinoid products were accompanied with a certificate of analysis that meets the requirements of rule 901:14-2-15 of the Administrative Code;
(i) The certificate of analysis matches the batch or lot used in the production of the hemp-derived cannabinoid products by the processor; and
(ii) The certificate of analysis was generated by a laboratory which meets the requirements of rule 901:14-2-14 of the Administrative Code.
(d) Testing as specified in paragraph (C)(2) of this rule is required only for the initial production run for each new intermediate hemp-derived cannabinoid product utilized in the product formulation. This exception remains valid provided the same lot or batch of intermediate hemp-derived cannabinoid product is utilized and the formulation for the finished product remains unchanged.
Last updated November 9, 2026 at 7:47 AM
Supplemental Information